Recombinant IL-15 antibody

Catalog No. ABIN7488621

The Mouse Monoclonal anti-IL-15 antibody has been validated for ELISA. It is suitable to detect IL-15 in samples from Human.

Quick Overview for Recombinant IL-15 antibody (ABIN7488621)

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IL-15 antibody is un-conjugated

Application: ELISA

Clone: 12B11E5

Product Details anti-IL-15 Antibody

Purpose: Anti-Human IL15 (12B11E5) mAb, Mouse IgG1

Immunogen: Anti-Human IL15 (12B11E5) MAb, Mouse IgG1 is a monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a Mouse monoclonal antibody with mouse IgG1 constant domain. The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with IL15.

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Storage: -20 °C

Target Details for IL-15

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Alternative Name: IL15

Background: Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells, cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

Pathways: JAK-STAT Signaling, Glycosaminoglycan Metabolic Process